Bill
Bill > A1322
NJ A1322
NJ A1322Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.
summary
Introduced
01/09/2024
01/09/2024
In Committee
01/09/2024
01/09/2024
Crossed Over
Passed
Dead
01/12/2026
01/12/2026
Introduced Session
2024-2025 Regular Session
Bill Summary
This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to the patient undergoing chemotherapy. Dihydropyrimidine dehydrogenase deficiency is a disorder in which the human body experiences difficultly or is unable to breakdown chemotherapy drugs leading to a harmful reaction. Under the bill, health insurance plans in this State are to cover expenses incurred in conducting one test for dihydropyrimidine dehydrogenase deficiency every year.
AI Summary
This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency, a disorder that can cause a harmful reaction to chemotherapy drugs, before the patient undergoes chemotherapy. It also requires health insurance plans in New Jersey to cover the cost of one such test per year, as well as any necessary prescription drug treatment for the deficiency. The bill directs the Commissioner of Health and the Department of Banking and Insurance to promulgate rules and regulations to implement these provisions, and it takes effect 90 days after enactment.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Introduced, Referred to Assembly Health Committee (on 01/09/2024)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2024/A1322 |
| BillText | https://pub.njleg.gov/Bills/2024/A1500/1322_I1.HTM |
Loading...